I am very happy that I have been allowed to reopen my practice and help people through a method I deeply care about.

Based on the guidelines of the BAG I have put in place the following safety measures for my practice. For the protection of us all, I ask you to read and observe these rules carefully.

Thus, even in these uncertain times, we create a safe place of well-being.

– If you have symptoms that indicate COVID-19 disease (cough, fever, respiratory problems, loss of sense of smell and taste) you may unfortunately NOT come to therapy. I advise you to contact a doctor and isolate yourself.

– Please do not come to the practice until shortly before the start of treatment to avoid long waiting times in waiting area.

– Please wash your hands thoroughly with soap after entering the practice. If necessary hand disinfectants are also available.

– In order to be able to guarantee the distance in the waiting area, we have reduced the number of chairs.

Magazines and children’s toys have been removed.

– We have to do without handshakes.  We will have to make do with a smile.

– Since I cannot maintain the distance of 2m during body therapy, I will wear a hygiene mask during the hand-on part of the treatment. As a client you are not required to wear a mask, but I am happy for you to do so, if you so wish.  For clients who belong to the At Risk Group (see appendix below), it is recommended that you do wear a hygiene mask.

– Thorough washing of hands before and after each treatment is a matter of course for me, as well as the extensive ventilation of the practice room during and after each session.

– Surfaces, door handles, light switches, water taps, WC flush buttons etc. will be disinfected several times a day.

I look forward to seeing you again and thank you very much for respecting and following of these rules.

Appointments can be made, as usual here: https://availabilitythisweek.as.me/

Appendix

(English below)

–Anhang 61
(Art. 10b Abs. 3)
https://www.admin.ch/opc/de/classifiedcompilation/20200744/index.html#pp6ahref0
Kategorien besonders gefährdeter Personen

1. Bluthochdruck
   – Arterielle Hypertonie mit Endorganschaden
   – Therapie-resistente arterielle Hypertonie
2. Herz-Kreislauf-Erkrankungen
   2.1 Generelle Kriterien
   – Funktionelle Klasse NYHA ³ II und NT-Pro BNP > 125 pg/ml
   – Patient/innen mit ³ 2 kardiovaskulären Risikofaktoren (einer davon Diabetes oder arterielle
   Hypertonie)
   – Vorgängiger Schlaganfall und/oder symptomatische Vaskulopathie
   – Chronische Niereninsuffizienz (Stadium 3, GFR <60ml/min) 2.2 Andere Kriterien 2.2.1 Koronare Herzkrankheit – ACS (STEMI und NSTEMI) in den letzten 12 Monaten – Symptomatisches chronisches Koronarsyndrom trotz medizinischer Therapie (unabhängig von allfälliger vorheriger Revaskularisierung) 2.2.2 Erkrankung der Herzklappen – Native Klappenstenose und/oder Regurgitation zusätzlich zu mindestens einem generellen Kriterium – Mittelschwere oder Schwere Stenose und/oder Regurgitation – Jeglicher chirurgischer oder perkutanter Klappenersatz 2.2.3 Herzinsuffizienz – Patient/in mit funktioneller Klasse NYHA ³ II oder NT-Pro BNP > 125pg/ml trotz medizinischer
   Therapie jeglicher LVEF (HFpEF, HFmrEF, HFrEF)
   – Kardiomyopathie jeglicher Ursache
   – Pulmonalarterielle Hypertonie
   2.2.4 Arrhythmie
   – Jegliche Arrhythmie (Bradycardie / Tachycardie) zusätzlich zu einem generellen Kriterium
   – Vorhofflimmern
   – Vorgängige Schrittmachereinlage (inkl. ICD und/oder CRT Implantation) zusätzlich zu einem generellen
   Kriterium
   – Vorgängige Ablation zusätzlich zu einem generellen Kriterium
   2.2.5 Erwachsene mit kongenitaler Herzerkrankung
   – Jegliche kongenitale Herzerkrankung
3. Chronische Atemwegserkrankungen
   – Chronisch Obstruktive Lungenerkrankungen GOLD Stadium II-IV
   – Lungenemphysem
   – Unkontrolliertes, insbesondere schweres Asthma bronchiale
   – Interstitielle Lungenerkrankungen
   – Aktiver Lungenkrebs
   – Pulmonalarterielle Hypertonie
   – Pulmonalvaskuläre Erkrankung
   – Aktive Sarkoidose
   – Zystische Fibrose
   – Chronische Lungeninfektionen (atypische Mykobakteriosen, Bronchiektasen etc.)
   – Beatmete Patient/innen
   – Schlafapnoe bei Vorhandensein weiterer Risikofaktoren (z.B. Adipositas)
4. Diabetes
   – Diabetes mellitus, mit Spätkomplikationen oder einem HbA1c von > 8%
5. Erkrankungen/Therapien, die das Immunsystem schwächen
   – Schwere Immunsuppression (z.B. CD4+< 200μl)
   – Neutropenie ≥1 Woche
   – Lymphozytopenie <0.2×109/L
   – Hereditäre Immundefekte
   – Einnahme von Medikamenten, die die Immunabwehr unterdrücken (wie z. B. Langzeit-Einnahme
   von Glukokortikoide, monoklonale Antikörper, Zytostatika, etc.)
   – Aggressive Lymphome (alle Entitäten)
   – Akute Lymphatische Leukämie
   – Akute Myeloische Leukämie
   – Akute Promyelozytenleukämie
   – T-Prolymphozytenleukämie
   – Primäre Lymphome des zentralen Nervensystems
   – Stammzelltransplantation
   – Amyloidose (Leichtketten (AL)- Amyloidose)
   – Aplastische Anämie unter immunsuppressiver Therapie
   – Chronische Lymphatische Leukämie
   – Asplenie / Splenektomie
   – Multiples Myelom
   – Sichelzellkrankheit
6. Krebs
   – Krebs unter medizinischer Behandlung

Note 6

(Article 10b(3))

Categories of particularly vulnerable persons

1. high blood pressure

– Arterial hypertension with end organ damage

– Therapy resistant arterial hypertension

2. cardiovascular diseases

2.1 General criteria

– Functional class NYHA ³ II and NT-Pro BNP > 125 pg/ml

– Patients with ³ 2 cardiovascular risk factors (one of them diabetes or arterial hypertension)

– Prior stroke and/or symptomatic vasculopathy

– Chronic renal failure (stage 3, GFR <60ml/min)

2.2 Other criteria

2.2.1 Coronary heart disease

– ACS (STEMI and NSTEMI) in the last 12 months

– Symptomatic chronic coronary syndrome despite medical therapy (independent from any previous revascularization)

2.2.2 Disease of the heart valves

– Native valve stenosis and/or regurgitation in addition to at least one general criterion

– Medium or severe stenosis and/or regurgitation

– Any surgical or percutaneous valve replacement

2.2.3 Heart failure

– Patient with functional class NYHA ³ II or NT-Pro BNP > 125pg/ml despite medical therapy of any LVEF (HFpEF, HFmrEF, HFrEF)

– cardiomyopathy of any cause

– Pulmonary arterial hypertension

2.2.4 Arrhythmia

– Any arrhythmia (bradycardia / tachycardia) in addition to a general criterion

– Atrial fibrillation

– Preliminary pacemaker insertion (incl. ICD and/or CRT implantation) in addition to a general

Criterion

– Prior ablation in addition to a general criterion

2.2.5 Adults with congenital heart disease

– Any congenital heart disease

3. chronic respiratory diseases

– Chronic Obstructive Pulmonary Diseases GOLD Stage II-IV

– Emphysema of the lungs

– Uncontrolled, especially severe bronchial asthma

– Interstitial lung diseases

– Active lung cancer

– Pulmonary Arterial Hypertension

– Pulmonary vascular disease

– Active Sarcoidosis

– Cystic Fibrosis

– Chronic lung infections (atypical mycobacterioses, bronchiectasis etc.)

– Ventilated patients

– Sleep apnoea in the presence of other risk factors (e.g. obesity)

4. diabetes

– Diabetes mellitus, with late complications or an HbA1c of > 8%.

5. diseases/therapies that weaken the immune system

– Severe immunosuppression (e.g. CD4+< 200μl)

– Neutropenia ≥1 Week

– Lymphocytopenia <0.2×109/L

– Hereditary immunodeficiencies

– Taking medication that suppresses the immune system (e.g. long-term use of of glucocorticoids, monoclonal antibodies, cytostatic drugs, etc.)

– Aggressive lymphomas (all entities)

– Acute lymphatic leukemia

– Acute Myeloid Leukemia

– Acute promyelocytic leukemia

– T-prolymphocytic leukemia

– Primary lymphomas of the central nervous system

– Stem cell transplantation

– Amyloidosis (light chain (AL)- amyloidosis)

– Aplastic anaemia under immunosuppressive therapy

– Chronic Lymphatisc

5. diseases/therapies that weaken the immune system

– Severe immunosuppression (e.g. CD4+< 200μl)

– Neutropenia ≥1 Week

– Lymphocytopenia <0.2×109/L

– Hereditary immunodeficiencies

– Taking medication that suppresses the immune system (e.g. long-term use of of glucocorticoids, monoclonal antibodies, cytostatic drugs, etc.)

– Aggressive lymphomas (all entities)

– Acute lymphatic leukemia

– Acute Myeloid Leukemia

– Acute promyelocytic leukemia

– T-prolymphocytic leukemia

– Primary lymphomas of the central nervous system

– Stem cell transplantation

– Amyloidosis (light chain (AL)- amyloidosis)

– Aplastic anaemia under immunosuppressive therapy

– Chronic Lymphatic Leukemia

– Asplenia / Splenectomy

– multiple myeloma

– Sickle cell disease

6. cancer

– Cancer under medical treatment

Translated with www.DeepL.com/Translator